Clinical Trial Update: Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial of SLC-391 in combination with pembrolizumab for non-small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• SLC-391 (SLC-391)

Snippet

Sponsor: SignalChem Lifesciences Corporation | Conditions: Lung Cancer, Nonsmall Cell, Lung Cancer Stage IV | Phase 1, Phase 2 | Status: TERMINATED